Abstract Despite development of new therapies, metastatic colorectal cancer (mCRC) largely remains an incurable disease. Approximately 2-6 % of colorectal cancers harbor NRAS mutations. The anti-VEGF antibody bevacizumab is a backbone of most therapeutic regimens; however, biomarkers predicting its activity are not known. We report two cases of mCRC with a Q61K NRAS mutation that had a favorable response to bevacizumab and the histone deacetylase inhibitor valproic acid. In contrast, none of ten patients with wild-type NRAS or unknown NRAS status and mutated KRAS (NRAS and KRAS mutations are mutually exclusive) responded to the same regimen. These results suggest that NRAS mutation merits further investigation as a potential biomarker predicting the efficacy of bevacizumab-based treatment.
Introduction
Colorectal cancer is the third most frequent cause of death from cancer in men and women in the USA, and it is estimated that more than 49,000 Americans died of this disease in 2011 [1] . Metastatic colorectal cancer is not curable, except for a small proportion of patients with isolated liver metastasis, and the median overall survival usually does not exceed 2 years [2, 3] . Standard treatment options include oxaliplatin or irinotecan in combination with 5-fluorouracil/leucovorin or capecitabine. These cytotoxic drugs may be combined with targeted agents such as monoclonal antibodies cetuximab or panitumumab, which target epidermal growth factor receptor (EGFR), or the monoclonal antibody bevacizumab, which targets vascular endothelial growth factor (VEGF) [2] [3] [4] . While patients with a mutated KRAS oncogene are known not to derive benefit from anti-EGFR antibodies, there is no marker predicting response to bevacizumab. As a result, bevacizumab is widely used even though only a subset of patients derives benefit from it. He was then referred to the Clinical Center for Targeted Therapy. The molecular profile of the tumor sample from the left hepatic metastasectomy showed wild-type (wt) KRAS, wt BRAF, wt EGFR, wt KIT, wt PIK3CA, intact PTEN expression, and a Q61K NRAS mutation (181C>A).
In April 2009, he initiated an investigational therapy with carboplatin and a nucleoside antimetabolite. His tumors were slowly growing until he was found to have unequivocal disease progression in the lungs and liver in September 2009. Then he initiated a clinical trial with the anti-VEGF monoclonal antibody bevacizumab (11 mg/kg IV on days 1 and 15 of 28 days) in combination with histone deacetylase (HDAC) inhibitor valproic acid (5.3 mg/kg PO daily). The first restaging with CT of chest, abdomen, and pelvis showed about 11 % improvement per Response Evaluation Criteria in Solid Tumors (RECIST), and this was maintained for 13.5 months until November 2010 ( Fig. 1 ) [5] . Western blotting of peripheral mononuclear blood cells obtained before the first study drug administration and on day 15 of cycle 1 confirmed increased histone acetylation (data not shown).
Patient 2 was a 35-year-old man, who was diagnosed with sigmoid adenocarcinoma in August 2005; he then underwent sigmoid resection, which revealed moderately differentiated adenocarcinoma infiltrating through the bowel, and six out of 13 lymph nodes were infiltrated. A CT of chest, abdomen, and pelvis showed no evidence of distant metastasis (pT3pN2M0). He received adjuvant chemotherapy with FOLFOX for 6 months. He was disease-free until April 2008, when he was diagnosed with left hepatic lobe metastasis. He received palliative chemotherapy with FOLFOX in combination with bevacizumab from April to October 2008, with response shown by attenuated FDG uptake on positron emission tomography (PET). The patient then underwent regional treatment for liver metastasis with a Cyberknife. Eventually, he presented with recurrent liver metastases and resumed chemotherapy with FOLFOX in combination with bevacizumab from July to October 2009, with a response noted in a follow up FDG-PET. In November 2009, he underwent an explorative laparotomy with the intent to remove liver metastasis, but this with aborted due to a perioperative finding of peritoneal carcinomatosis. In December 2009, he initiated chemotherapy with FOLFIRI and bevacizumab, but because of poor tolerance, this treatment was changed after seven cycles to irinotecan, capecitabine (XELIRI), and cetuximab, which continued until disease progression in November 2010. Starting in January 2011, he initiated an experimental phase I therapy with a recombinant IgG1 antibody product consisting of two antibodies against EGFR. At the time of disease progression in March 2011, he initiated treatment with a p38 mitogen-activated-protein kinase (MAPK) inhibitor and progressed on that in May 2011. Then he was referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. The molecular profile of the tumor sample from the primary tumor showed wt KRAS, and additional analysis from the omental metastasis revealed a Q61K NRAS mutation and V272M+R273C TP53 mutations. The tumor showed wt BRAF, wt EGFR, wt KIT, wt PIK3CA, and no aberrations in the additional 35 oncogenes tested in the panel.
In July 2011, he initiated a clinical trial with the anti-VEGF monoclonal antibody bevacizumab (11 mg/kg IV on days 1 and 15 of 28 days) in combination with the HDAC inhibitor valproic acid (5.3 mg/kg PO daily). The first restaging CT of the chest, abdomen, and pelvis after 8 weeks of therapy showed a 27 % improvement, and the second restaging after 16 weeks of therapy showed a 35 % improvement per RECIST compared to baseline (Fig. 2) . He continues on therapy for 8+ months.
We treated additional ten patients, who had metastatic colorectal cancer with wt NRAS (n=3) or unknown NRAS status and mutated KRAS (n=7, KRAS and NRAS mutations are mutually exclusive), and none of the patients experienced any tumor shrinkage per RECIST. Their median progression-free survival was 1.8 months (range, 0.3-3.9 months).
Discussion
We report two cases of heavily pretreated patients with metastatic colorectal cancer and a NRAS Q61K mutation treated with anti-VEGF monoclonal antibody bevacizumab and the HDAC inhibitor valproic acid. Both patients were heavily pretreated with standard therapies including bevacizumab. Both patients demonstrated tumor shrinkage per RECIST at the time of first restaging, which lasted for more than 13 months in patient 1. Patient 2 has achieved partial response and continued on therapy at the time of this report for 8+ months. None of the ten patients with metastatic colorectal cancer and wt NRAS or mutated KRAS (KRAS mutations do not coexist with NRAS mutations) treated on the same regimen showed prolonged stable disease or tumor regression.
NRAS mutations occur in subsets of diverse solid tumors, with the highest prevalence (14-30 %) in malignant melanoma [6] [7] [8] . NRAS mutations have been reported in 2-6 % of patients with colorectal cancers and, in a retrospective analysis, were associated with low responses to cetuximab and chemotherapy [6, 7, 9] . NRAS belongs to a family of small G proteins with three homologues (HRAS, NRAS, and KRAS) coded by different RAS gene loci. RAS activates MAPK and PI3K/AKT/mTOR signaling, which are two major pathways involved in the progression of multiple cancers [10] . In vitro studies link NRAS function to antiapoptotic signaling [11] . Preclinical models in a genetically engineered mouse demonstrated that KRAS mutation in colonic epithelium promote hyperproliferation via MEK signaling, whereas epithelial cells with NRAS mutation suppressed apoptosis [12] . In addition, preclinical models using cell line-derived xenografts with knocked out MEK expression demonstrated decreased angiogenesis and tumor growth compared to xenografts with intact MEK [13] . Therefore, it is conceivable that aberrations activating the MAPK pathway can promote angiogenesis. However, eight of ten patients with metastatic colorectal cancer with wt NRAS (n=3) or unknown NRAS status (n=7) had KRAS mutations in codon 12 or 13, and their outcomes on bevacizumab and valproic acid were dismal (of note, five of these patients also tested negative for BRAF mutations).
The role of NRAS mutations in selecting therapeutic regimens for cancer is currently unknown. Preclinical models with cell lines from different human cancers with NRAS mutations showed inhibition when treated with the MEK inhibitor CI-1040, and human colon cancer xenografts with NRAS mutations were sensitive to the MEK inhibitor AZD6244 [14, 15] . In addition, preclinical data on melanoma cell lines and early clinical observations suggest that melanomas with NRAS mutations are sensitive to HSP90 inhibitors [16, 17] .
Bevacizumab is an anti-VEGF monoclonal antibody, which, in most cancers, has only modest activity when given as a single agent but prolongs survival in combination with chemotherapy in several metastatic cancers [4, 18, 19] . Survival prolongation is approximately 2 months, and it is plausible that a small subset of patients benefit more substantially while most patients do not. Valproic acid, widely used for treating seizures, is also a HDAC inhibitor. Inhibiting histone deacetylase activity results in histone acetylation, which is associated with up-regulated gene transcription [20] . By promoting gene transcription, valproic acid induces differentiation, growth inhibition, and apoptosis [21] . Combinations of antiangiogenic agents and HDAC inhibitors are expected to have synergistic antiangiogenic activity [22] [23] [24] .
The mechanism of action explaining the salutary effect of bevacizumab in these two patients with colorectal cancer and a Q61K NRAS mutation remains unclear. First, the effect may be due to bevacizumab. Indeed, these patients were previously treated on bevacizumabcontaining regimens for approximately 22 and 13 months, Fig. 2 Imaging showing response to bevacizumab and vaproic acid in patient 2. The baseline CT of the chest, abdomen, and pelvis of patient 2 shows ascites, right lung pleural-based nodule, and peritoneal metastases. After 8 weeks of therapy, there is improvement in the size of all lesions with resolution of ascites respectively, before showing progression. However, with their prior therapy, the role of bevacizumab versus combination chemotherapy such as FOLFOX or FOLFIRI is unclear. Alternatively, it is possible that the addition of valproic acid contributed to therapeutic benefit in these cases since bevacizumab has only modest activity as single agent [18] . In theory, epigenetic modulation with valproic acid, which promotes transcription of tumor suppressor genes, may contradict the antiapoptotic effect of NRAS mutations and, in combination with bevacizumab, lead to enhanced antiangiogenesis. Alternatively, bevacizumab and valproic acid may induce autophagy to the point of autophagic cell death. Finally, bevacizumab and valproic acid may inhibit a critical, as yet unknown, pathway activated by NRAS. It is, however, conceivable that the therapeutic effect seen is due to bevacizumab, and the fact that single agent activity occurs in only a minority of patients with colorectal cancer is consistent with this notion, especially if NRAS mutation is a biomarker of response (since NRAS mutations occur in a minority of patients with colorectal cancer). NRAS mutations may serve as potential biomarkers to predict anticancer effect of bevacizumab and valproic acid. Nevertheless, our observations should be interpreted with caution. Even though it is possible that NRAS mutations can lead to increased angiogenesis, they are not necessarily predictive for response to bevacizumab.
Bevacizumab is an essential component of nearly all standard-of-care regimens for metastatic colorectal cancer [2, 4] . Despite being a targeted agent, which apparently is effective in only a small subset of patients, the relevant target or biomarker predicting its activity has not been identified. To understand the underlying molecular basis of efficacy, a bedside-to-bench foray has to be applied, and preclinical experiments in NRAS mutant colorectal cancer models need to be designed. Further, preclinical and clinical studies are warranted to investigate the role of NRAS mutation in bevacizumab-based therapies in colorectal cancer.
